The reasons for these observations are still unclear; however, we might speculate that the efficacy of ERβ agonists in reducing melanoma growth might depend not only on the presence of the receptor but also on other particular features of each melanoma, such as the oncogenic mutation status (NRAS, BRAF) of the tumor. This evidence concerns the gene ESR2 and melanoma.